Boitumelo Semete-Makokotlela
Boitumelo Semete-Makokotlela is the CEO of the South African Health Products Regulatory Authority, recently mentioned in the context of overseeing the registration process for new HIV prevention medications in South Africa amidst ongoing challenges with Pepfar funding.
Not in the pool (under ¢1).
Recent news mentions
Boitumelo Semete-Makokotlela is the head of the South African Health Products Regulatory Authority, Sahpra.
The six-monthly anti-HIV jab could be in 360 clinics by February. Who should get the first doses? – The Mail & Guardian
South Africa· 2025-10-20
Boitumelo Semete-Makokotlela is the CEO of Sahpra, overseeing the expedited review of lenacapavir.
SA plans anti-HIV jab roll-out at hundreds of clinics by April – The Mail & GuardianSouth Africa· 2025-09-01
Boitumelo Semete-Makokotlela is the chief executive of the South African Health Products Regulatory Authority.
SA gets R520 million to buy the twice-a-year anti-HIV jab – but there’s a snag – The Mail & GuardianSouth Africa· 2025-07-16
Boitumelo Semete-Makokotlela is the chief executive of Sahpra, who discussed the risks of unregulated ketamine use.
Elon Musk, depression and South Africa’s cowboy ketamine clinics – The Mail & GuardianSouth Africa· 2025-06-18
Boitumelo Semete-Makokotlela is the chief executive of Sahpra and is open to the rescheduling of scheduled substances.
Monthly prescription rule blocks ADHD treatment for South African children – The Mail & GuardianSouth Africa· 2025-06-09
Boitumelo Semete-Makokotlela is the CEO of the South African Health Products Regulatory Authority.
The six-monthly anti-HIV jab could end Aids in SA by 2032 – The Mail & GuardianSouth Africa· 2025-04-09
Boitumelo Semete-Makokotlela is the CEO of Sahpra, involved in the registration of lenacapavir.
Embassy confirms Pepfar projects will restart, despite Trump aid ban – The Mail & GuardianSouth Africa· 2025-02-12